News

Oculis Set to Showcase Breakthrough Therapies at Major Conferences

Oculis Set to Showcase Breakthrough Therapies at Major Conferences

Oculis Unveils New Therapies at Leading Ophthalmology Events

Oculis Holding AG (NASDAQ: OCS / ICX: OCS.IC), a global biopharmaceutical company dedicated to addressing significant unmet needs in ophthalmic and neuro-ophthalmic diseases, is set to present its innovative late-stage pipeline at several key ophthalmology conferences. With presentations confirmed for Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, and the Retina World Congress (RWC), Oculis aims to share advancements that could greatly impact the treatment landscape.

Key Highlights of the Presentations

The presentations will feature crucial insights from the DME AWARE Delphi Study, specifically focusing on unmet needs in diabetic macular edema (DME) patient management. Esteemed experts will share the interim results that underline areas for improvement. Oculis will also showcase data from the Phase 3 DIAMOND program concerning OCS-01 eye drops, which are being developed as the first non-invasive treatment option for DME. This innovative approach responds to unmet needs related to early treatments and inadequate responses to existing standards of care.

Moreover, insights from the Phase 2b RELIEF trial examining Licaminlimab (OCS-02) in dry eye disease (DED) will be discussed. This study has yielded promising results, emphasizing the potential for genetic biomarkers to direct personalized treatment strategies for DED patients. Licaminlimab represents a transformative step in treating this condition, which has long been characterized by trial-and-error approaches.

Conference Presentation Details

Specific details about each presentation include:

Eyecelerator 2025

Presentation Title: Company showcases – Retina: TKI and Drug Delivery
Presenter: Sharon Klier, M.D., Chief Development Officer
Date/Time: Friday, May 2, 2025, 1:30 PM – 3:00 PM MST

ARVO Annual Meeting 2025

Presentation Titles:
Interim results of the DME AWARE Delphi Study
Presenter: Anat Loewenstein, M.D.
Date/Time: Monday, May 5, 2025, 3:00 PM – 4:45 PM MST

BCVA and CST Improvement with OCS-01 Eye Drops in DME
Presenter: Carl Danzig, M.D.
Date/Time: Wednesday, May 7, 2025, 10:15 AM – 12:00 PM MST

Licaminlimab in treating dry eye disease
Presenter: Anat Galor, M.D.
Date/Time: Thursday, May 8, 2025, 8:00 AM – 9:45 AM MST

Retina World Congress 2025

Presentation Titles:
Wet AMD, DR, RVO – Part 2, Panel Discussion
Participant: Riad Sherif, M.D., Chief Executive Officer
Date/Time: Thursday, May 8, 2025, 11:25 AM – 11:59 AM ET

BCVA and CST Improvement with OCS-01 Eye Drops
Presenter: David Almeida, M.D.
Date/Time: Thursday, May 8, 2025, 6:08 PM – 6:13 PM ET

The Experts Behind the Innovations

Anat Loewenstein, M.D., MHA, a leading authority in retina and ophthalmology, will share insights into patient management strategies during the presentations. Her extensive background and numerous scholarly contributions make her a crucial figure in the advancements of DME care.

Additionally, Carl Danzig, M.D., and Anat Galor, M.D., bring their expertise in retinal diseases and dry eye treatment to the forefront, emphasizing research and new therapeutic applications that can better serve patients.

David Almeida, M.D., M.BA., Ph.D., FRCSC, DABO, will further expand on the clinical landscape with valuable data stemming from his participation in significant trials, thus adding another layer to Oculis’ commitment to innovative treatment solutions.

About Oculis and Its Innovative Pipeline

Oculis focuses on creating innovative treatment options for eye diseases that heavily impact quality of life. The company’s pipeline includes OCS-01, an eye drop candidate specifically for diabetic macular edema (DME), and Licaminlimab (OCS-02), aimed at treating dry eye disease (DED). With a robust research and development strategy, Oculis is set to revolutionize how these conditions are managed, prioritizing non-invasive solutions and personalized medicine.

For those seeking further information about Oculis' initiatives and presentations at upcoming conferences, you can visit www.oculis.com.

Frequently Asked Questions

What is Oculis focused on at these conferences?

Oculis is highlighting its innovative late-stage pipeline, focusing on treatments for diabetic macular edema (DME) and dry eye disease (DED).

When will Oculis present its findings?

Oculis will present at Eyecelerator 2025, ARVO Annual Meeting, and the Retina World Congress in early May 2025.

Who are the key presenters at Oculis' sessions?

Notable presenters include Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, and Dr. David Almeida, each bringing significant expertise in ophthalmology.

What is the significance of the OCS-01 eye drops?

OCS-01 aims to be the first non-invasive treatment option for DME, offering an alternative to current invasive therapies.

How does Licaminlimab aim to transform DED treatment?

Licaminlimab is designed to utilize genetic biomarkers for personalized treatment, turning a traditionally trial-driven process into a more targeted approach.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Apex Dental's Growth Shines in Inc. 5000 Ranking

Updated Category News Views 5

Another Year, Another Milestone for Apex Dental Let's talk about steady growth. Apex Dental Partners has made it onto the Inc. 5000 list for the eighth straight year, landing at No. 3,850. Quite a feat, considering this list only features America's fastest-growing private companies. Apex isn't just maintaining its position out of sheer luck. Revenue shot up by 67% over...

Continue Reading
Infrared Imaging Expands with AI, SWIR: Tech Trends

Updated Category News Views 5

Infrared Imaging: The Backbone of Future Tech Kinda wild how infrared imaging's become a hot topic in tech circles. With the market expected to jump from USD 9.2 billion in 2026 to a hefty USD 12.6 billion by 2031, averaging a 6.4% growth rate, there's plenty to chew on. Even if you ain't the analytical type, it ain't hard to spot where the money's flowing. Infrared's...

Continue Reading
EZ Elephant's Ladder-Free Gutter Fix Debuts at Expo

Updated Category News Views 4

A New Leaf in Gutter Maintenance From the ground up, EZ Elephant is redefining how we tackle gutter maintenance. Picture it: never having to teeter on that wobbly ladder again just to unclog your gutters. This American-made solution, showcased at the Western Roofing Expo from September 27–29, 2026, is a game changer. Check out Booth #834 to see this marvel of innovation...

Continue Reading
RunVermont Revamps City Marathon, Adds Half for 2027

Updated Category News Views 4

Straight outta Burlington, the M&T Bank Vermont City Marathon is giving its course a facelift and, get this, throwing a half marathon into the mix for 2027. It's about time they shook things up, considering how this race is supposed to be one of the most welcoming on the block. I mean, you're talking about a marathon that's practically been the crown jewel of Vermont's...

Continue Reading
First Lady Steals NYSE Show, Investors Eye Stakes

Updated Category News Views 4

Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...

Continue Reading
Epiclay: Game Changer for Sculptors Debuts

Updated Category News Views 11

Epiclay™ Brings New Energy to Sculpting World Folks, if ever there was a time to break the mold, it’s now, and Ace of Clay’s got us covered with Epiclay™—a fresh take on polymer clay that’s turning heads in the sculpture circuit. Over four long years, Ace of Clay, a brand that's gathered a rather colorful following through captivating sculptures and detailed...

Continue Reading
Newmark's $482.5M Loan Fuels Steamboat Resort Expansion

Updated Category News Views 4

Newmark Banks on Steamboat's Future Diving headfirst into the deep end, Newmark (NASDAQ: NMRK) just roped in a colossal $482.5 million loan for a new gem in Steamboat Springs, Colorado. Inking a deal of this magnitude ain't your everyday rinse-and-repeat; it's a bold move that speaks volumes about where the big shots think value's heading. The Financial Fuel: GoldenTree...

Continue Reading
1.8M Moves in England: The Admin Maze Explained

Updated Category News Views 5

Navigating the Address Change Labyrinth Every time that welcome mat rolls out in a new spot, you're signing up for a mountain of paperwork. Sloth Move just painted a picture of the administrative mess awaiting those 1.8 million English households that decided 'new view, new digs' last year. Their analysis highlights why moving home means more than packing boxes—it's...

Continue Reading
Synopsys-TSMC Collaboration Drives AI System Evolution

Updated Category News Views 4

Synopsys and TSMC: The New Power Couple in AI Ah, the world of semiconductors—where the chips are small but the stakes are colossal. Once again, Synopsys and TSMC have thrown their hats into the ring, diving headfirst into yet another ambitious collaboration. Their latest mission? To fast-track the evolution of AI systems through a suite of innovations strapped to...

Continue Reading
Oracle Harnesses AI to Streamline Healthcare Payments

Updated Category News Views 8

Oracle Steps into Healthcare's Payment Arena You ever try solving a puzzle with half the pieces missing? Well, that's exactly what healthcare orgs have been doing with their revenue cycles. Oracle (NYSE:ORCL) thinks it’s got the missing pieces. They've announced some slick AI capabilities to grease the wheels of healthcare revenue management. But hey, I've seen grand...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering High-Grade Gold Opportunities Amid Market Shifts

Updated Category News Views 75

Unveiling Potential in the Gold Market In a rapidly evolving gold market, the recent surge in gold prices above $4,300 per ounce has sparked significant interest in high-grade gold deposits. This market scenario has created a unique advantage for firms showcasing premium quality deposits, as major new gold discoveries have become increasingly rare. Strategic Players in...

Continue Reading
Coppernico Metals Enhances Option Agreement to Boost Exploration

Updated Category News Views 113

Coppernico Metals Strengthens Exploration Efforts in Peru VANCOUVER, British Columbia — Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) is excited to announce the amendments made to its option agreements to bolster its exploration programs at the Sombrero Project. Through its subsidiary, Sombrero Minerales SAC, the company has taken significant steps to...

Continue Reading
Apple Inc. Shares See Pre-Market Weakness: Insights and Analysis

Updated Category News Views 72

Apple's Share Performance in Pre-Market Trading Apple Inc. (NASDAQ: AAPL) recently experienced a notable decline in its stock during pre-market trading. Shares fell 2.03%, bringing them down to $221.32 from Thursday's close of $225.91. This unexpected drop can be attributed to the company’s cautious sales growth outlook for the upcoming quarter. Understanding the Recent...

Continue Reading
Mongolian Mining Corporation Joins OTCQX for Greater Reach

Updated Category News Views 85

Mongolian Mining Corporation Joins OTCQX for Enhanced Market Presence In an exciting development, Mongolian Mining Corporation, a prominent player in the high-quality washed hard coking coal sector, has made a significant advancement by listing on the OTCQX Best Market. This upgrade reflects the company's commitment to providing robust trading opportunities for U.S....

Continue Reading
ThreeD Capital Inc. Expands Stake in AI/ML Innovations Inc.

Updated Category News Views 281

ThreeD Capital Inc. Expands Stake in AI/ML Innovations Inc. ThreeD Capital Inc. (“ThreeD”) is a well-known Canadian venture capital firm that has recently strengthened its investment portfolio through a strategic acquisition. Through a private placement, ThreeD and its key associate Sheldon Inwentash have successfully acquired a substantial number of common shares of...

Continue Reading